All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert Opinions

Prof. Andrés Ferreri | ICML 2017 | Extranodal Marginal Zone Lymphoma and the use of clarithromycin

By Anne Villeneuve, Natasha Fort
Featured
Andrés Ferreri
Jun 22, 2017
Share:

Prof. Andrés Ferreri, from the San Raffaele Scientific Institute, Milan, IT, on the use of clarithromycin in Extranodal Marginal Zone Lymphoma:

Extranodal Marginal Zone Lymphoma and the use of clarithromycin

Share:
More about...
ICML 2017Indolent B-cell lymphomasMarginal zone lymphomaRare lymphomas

Related articles

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox